Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1111/ejh.13479

Type

Journal article

Journal

Eur J Haematol

Publication Date

11/2020

Volume

105

Pages

662 - 666

Keywords

COVID-19, SARS-CoV-2, infection, myeloma, outcome, therapy, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, COVID-19, Combined Modality Therapy, Disease Management, Forecasting, Hematopoietic Stem Cell Transplantation, Humans, Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Palliative Care, Pandemics, Recurrence, SARS-CoV-2, Salvage Therapy, Transplantation, Autologous, Treatment Outcome, United Kingdom